The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer

Tatsu Matsuzaki, Shinnosuke Ikemura, Shotaro Chubachi, Shingo Nakayama, Eri Iwami, Minako Sato, Takahiro Nakajima, Keisuke Eguchi, Takeshi Terashima

Research output: Contribution to journalArticle

Abstract

Objective. The aim of this retrospective study was to evaluate the prognostic factors for long-term survival (> 5 years) in patients with stage IV NSCLC. Methods. We reviewed 66 patients with stage IV NSCLC who were diagnosed at our hospital from 10/1/2002 to 9/30/2010. Results. In comparison to 58 patients who survived for < 5 years, 8 patients who survived for > 5 years were more likely to have an EGFR mutation positive, an early N status (N0, N1), and a single metastatic site. Age < 75 years, an early N status (N0, N1), and the absence of liver metastasis were independent prognostic factors. Among the patients who survived for >5 years, the rate of EGFR-TKI use was higher, the rate of disease control in patients who were treated with both cytotoxic drugs and an EGFR-TKI was higher, and progression-free survival was longer in patients who were treated with cytotoxic drugs and an EGFR-TKI in comparison to patients who survived for < 5 years. Conclusion. Our results suggest that age <75 years, an early N status (N0, N1), and the absence of liver metastasis may contribute to long-term survival in patients with stage IV NSCLC. We should take these results into consideration when deciding aggressive therapy.

Original languageEnglish
Pages (from-to)88-95
Number of pages8
JournalJapanese Journal of Lung Cancer
Volume57
Issue number2
Publication statusPublished - 2017 Apr 20
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Pharmaceutical Preparations
Disease-Free Survival
Retrospective Studies
Neoplasm Metastasis
Mutation
Liver

Keywords

  • Long-term survivor
  • Non-small cell lung cancer (NSCLC
  • Stage IV

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer. / Matsuzaki, Tatsu; Ikemura, Shinnosuke; Chubachi, Shotaro; Nakayama, Shingo; Iwami, Eri; Sato, Minako; Nakajima, Takahiro; Eguchi, Keisuke; Terashima, Takeshi.

In: Japanese Journal of Lung Cancer, Vol. 57, No. 2, 20.04.2017, p. 88-95.

Research output: Contribution to journalArticle

Matsuzaki, T, Ikemura, S, Chubachi, S, Nakayama, S, Iwami, E, Sato, M, Nakajima, T, Eguchi, K & Terashima, T 2017, 'The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer', Japanese Journal of Lung Cancer, vol. 57, no. 2, pp. 88-95.
Matsuzaki, Tatsu ; Ikemura, Shinnosuke ; Chubachi, Shotaro ; Nakayama, Shingo ; Iwami, Eri ; Sato, Minako ; Nakajima, Takahiro ; Eguchi, Keisuke ; Terashima, Takeshi. / The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer. In: Japanese Journal of Lung Cancer. 2017 ; Vol. 57, No. 2. pp. 88-95.
@article{3597c907a5024bdebce5e25fa40fdad6,
title = "The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer",
abstract = "Objective. The aim of this retrospective study was to evaluate the prognostic factors for long-term survival (> 5 years) in patients with stage IV NSCLC. Methods. We reviewed 66 patients with stage IV NSCLC who were diagnosed at our hospital from 10/1/2002 to 9/30/2010. Results. In comparison to 58 patients who survived for < 5 years, 8 patients who survived for > 5 years were more likely to have an EGFR mutation positive, an early N status (N0, N1), and a single metastatic site. Age < 75 years, an early N status (N0, N1), and the absence of liver metastasis were independent prognostic factors. Among the patients who survived for >5 years, the rate of EGFR-TKI use was higher, the rate of disease control in patients who were treated with both cytotoxic drugs and an EGFR-TKI was higher, and progression-free survival was longer in patients who were treated with cytotoxic drugs and an EGFR-TKI in comparison to patients who survived for < 5 years. Conclusion. Our results suggest that age <75 years, an early N status (N0, N1), and the absence of liver metastasis may contribute to long-term survival in patients with stage IV NSCLC. We should take these results into consideration when deciding aggressive therapy.",
keywords = "Long-term survivor, Non-small cell lung cancer (NSCLC, Stage IV",
author = "Tatsu Matsuzaki and Shinnosuke Ikemura and Shotaro Chubachi and Shingo Nakayama and Eri Iwami and Minako Sato and Takahiro Nakajima and Keisuke Eguchi and Takeshi Terashima",
year = "2017",
month = "4",
day = "20",
language = "English",
volume = "57",
pages = "88--95",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "2",

}

TY - JOUR

T1 - The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer

AU - Matsuzaki, Tatsu

AU - Ikemura, Shinnosuke

AU - Chubachi, Shotaro

AU - Nakayama, Shingo

AU - Iwami, Eri

AU - Sato, Minako

AU - Nakajima, Takahiro

AU - Eguchi, Keisuke

AU - Terashima, Takeshi

PY - 2017/4/20

Y1 - 2017/4/20

N2 - Objective. The aim of this retrospective study was to evaluate the prognostic factors for long-term survival (> 5 years) in patients with stage IV NSCLC. Methods. We reviewed 66 patients with stage IV NSCLC who were diagnosed at our hospital from 10/1/2002 to 9/30/2010. Results. In comparison to 58 patients who survived for < 5 years, 8 patients who survived for > 5 years were more likely to have an EGFR mutation positive, an early N status (N0, N1), and a single metastatic site. Age < 75 years, an early N status (N0, N1), and the absence of liver metastasis were independent prognostic factors. Among the patients who survived for >5 years, the rate of EGFR-TKI use was higher, the rate of disease control in patients who were treated with both cytotoxic drugs and an EGFR-TKI was higher, and progression-free survival was longer in patients who were treated with cytotoxic drugs and an EGFR-TKI in comparison to patients who survived for < 5 years. Conclusion. Our results suggest that age <75 years, an early N status (N0, N1), and the absence of liver metastasis may contribute to long-term survival in patients with stage IV NSCLC. We should take these results into consideration when deciding aggressive therapy.

AB - Objective. The aim of this retrospective study was to evaluate the prognostic factors for long-term survival (> 5 years) in patients with stage IV NSCLC. Methods. We reviewed 66 patients with stage IV NSCLC who were diagnosed at our hospital from 10/1/2002 to 9/30/2010. Results. In comparison to 58 patients who survived for < 5 years, 8 patients who survived for > 5 years were more likely to have an EGFR mutation positive, an early N status (N0, N1), and a single metastatic site. Age < 75 years, an early N status (N0, N1), and the absence of liver metastasis were independent prognostic factors. Among the patients who survived for >5 years, the rate of EGFR-TKI use was higher, the rate of disease control in patients who were treated with both cytotoxic drugs and an EGFR-TKI was higher, and progression-free survival was longer in patients who were treated with cytotoxic drugs and an EGFR-TKI in comparison to patients who survived for < 5 years. Conclusion. Our results suggest that age <75 years, an early N status (N0, N1), and the absence of liver metastasis may contribute to long-term survival in patients with stage IV NSCLC. We should take these results into consideration when deciding aggressive therapy.

KW - Long-term survivor

KW - Non-small cell lung cancer (NSCLC

KW - Stage IV

UR - http://www.scopus.com/inward/record.url?scp=85019547512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019547512&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85019547512

VL - 57

SP - 88

EP - 95

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 2

ER -